Key result
Left ventricular assist devices (LVAD) as a bridge to recovery induce physiological changes indicative of recovery, though clinical success remains limited.
Why the study?
Does left ventricular assist device (LVAD) support induce recovery in patients with myocarditis and dilated cardiomyopathy?
Does left ventricular assist device (LVAD) support induce recovery in patients with myocarditis and dilated cardiomyopathy?
LVADs show promise as a bridge to recovery in myocarditis and dilated cardiomyopathy by inducing favorable physiological changes, though clinical success remains limited and requires further study.
LVAD recovery signals do not yet support routine explant; leaves open optimal timing, adjunct therapies, and weaning protocols.
A new application for left ventricular assist devices (LVAD) is as a bridge to recovery. In the settings of myocarditis and dilated cardiomyopathy, LVAD support is accompanied by marked hemodynamic, neurohormonal, physiologic, cellular, and molecular changes indicative of recovery. Despite these changes, experience with clinical successes is limited. Further studies of topics such as the timing of LVAD implantation and explantation, adjunct medical and surgical therapy, and optimum LVAD weaning protocols might help improve the success of this promising technology.
No takes yet. Share an insight, caveat, or question.
Kumpati et al. (2001) conducted a review in Myocarditis and dilated cardiomyopathy. Left ventricular assist devices (LVAD) was evaluated. Left ventricular assist devices (LVAD) as a bridge to recovery induce physiological changes indicative of recovery, though clinical success remains limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: